Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry

MLA

Zimmermann, Heiner, et al. “Reduction of Immunosuppression Combined with Whole-Brain Radiotherapy and Concurrent Systemic Rituximab Is an Effective yet Toxic Treatment of Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (PCNS-PTLD): 14 Cases from the Prospective German PTLD Registry.” Annals of Hematology, vol. 100, no. 8, Aug. 2021, pp. 2043–50. EBSCOhost, https://doi.org/10.1007/s00277-021-04548-2.

APA

Zimmermann, H., Nitsche, M., Pott, C., Reinke, P., Babel, N., Hermann, R. M., Hauser, I. A., Hahn, D., Ritgen, M., Pietschmann, C., Klapper, W., Anagnostopoulos, I., & Trappe, R. U. (2021). Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry. Annals of Hematology, 100(8), 2043–2050. https://doi.org/10.1007/s00277-021-04548-2

Chicago

Zimmermann, Heiner, Mirko Nitsche, Christiane Pott, Petra Reinke, Nina Babel, Robert M. Hermann, Ingeborg A. Hauser, et al. 2021. “Reduction of Immunosuppression Combined with Whole-Brain Radiotherapy and Concurrent Systemic Rituximab Is an Effective yet Toxic Treatment of Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (PCNS-PTLD): 14 Cases from the Prospective German PTLD Registry.” Annals of Hematology 100 (8): 2043–50. doi:10.1007/s00277-021-04548-2.